Suzanne Lentzsch, MD, PhD
@SLentzsch
Director of the Myeloma & Amyloidosis Service @columbiacancer - Associate Editor @JCO_ASCO-Tweets are my own https://www.cuimc.columbia.edu/labs/lentzsch-lab/
#ASCO25 Looking forward to seeing CARTITUDE-1 long term presentation shortly! #mmsm 1 in 3 (32/97) patients alive and progression-free for ≥5 years - functional cure in my opinion. Simultaneous JCO pub, highlighted NY Times ascopubs.org/doi/10.1200/JC… nytimes.com/2025/06/03/hea…
Great honor to do this year’s #Crossfire medical debate on early treatment in myeloma with Dr @SLentzsch from @Columbia Myeloma Program. Thank you Dr. @szusmani & @MJHLifeSciences #PER 9th Annual Hematologic Malignancies Crossfire for inviting us! #mmsm
1/ Our call to action is out in @BloodAdvances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.
In another multicenter (@columbiacancer and @BrighamWomens) study of BCMA BsAb in AL Amyloidosis (including stage IIIb), brisk and deep hematologic responses translating into organ responses, despite short follow-up! Now we need: Prospective data Long term follow up to test…
#Myeloma Paper of the Day: Case series of elranatamab for relapsed &/or refractory advanced stage AL #amyloidosis finds 100% ORR & 67% CR rate; median time to heme response of 9 days (6-24), translating into cardiac & renal responses at 3-6 months: pubmed.ncbi.nlm.nih.gov/40712156/. #mmsm
Up next 💥Should we treat smoldering myeloma now? Yes or not ? 💥with @DrOlaLandgren and @SLentzsch chaired by @szusmani
@Myeloma_Society awards announced to celebrate Women in Myeloma🎉🎉well deserved achievements @mvmateos & @ElenaZamagni
The Phase III CARES trial of #anselamimab in #ALAmyloidosis did not meet its primary endpoint, but showed clinically meaningful benefit in a predefined high-risk subgroup. More details to follow at upcoming meetings. @BU_Amyloidosis astrazeneca.com/media-centre/p…
new era for AL Amyloidosis - efficacy of anti-fibril strategy - Anselamimab shows highly clinically meaningful improvement in survival and cardiovascular hospitalisation in prespecified patient subgroup @Amyloidosis_ARC @ISA_Amyloidosis astrazeneca.com/media-centre/p…
Save the date for the the 2026 International Symposium on Amyloidosis! Join leading clinicians, researchers, and scientists from around the globe at the premier meeting dedicated to amyloidosis and protein-folding diseases. Stay tuned for more details: isaamyloidosis.org/isa-symposium/
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study #mmsm #bmtsm @JCO_ASCO ascopubs.org/doi/full/10.12…
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma @JCO_ASCO #mmsm #bmtsm ascopubs.org/doi/10.1200/JC…
Once more congratulations @NoopurRajeMD for a very successful program lots of case discussions and inspiring educational lectures
@Myeloma_Society educational workshop in Marrakech with @NikhilMunshiMD @SagarLonialMD @myelomaMD @mbeksac56 @szusmani ..excellent talks and great cases.. stay tuned for accessing the web content.
📣 CALL FOR ABSTRACTS FOR #ESHMM2026! Present your work at the 8th Translational Research Conference on Multiple Myeloma ➡️ bit.ly/4cy6PCW 🗓 March 26-28, 2026 / Stockholm, Sweden 🇸🇪 Chairs: Hartmut Goldschmidt, @MyMKaiser, @SLentzsch #ESHCONFERENCES #Haematology #MMsm
🧬 Amyloidosis can be elusive - early detection is key. In our latest podcast, expert @MorieGertz breaks down what every clinician should know about spotting the signs and choosing the right diagnostic tests. 🎙️ Listen in: ow.ly/OjBV50WbrWi #HemOnc #amyloidosis
#Myeloma Paper of the Day: Retrospective study of AL #amyloidosis pts (n=130) w/ liver involvement finds median time to hepatic response (HepR) 21.5 mos; baseline ALP ≥4xULN predicted HepR; HemR, kappa isotype & front-line ASCT also predicted HepR: pubmed.ncbi.nlm.nih.gov/40509545/. #mmsm
Just out! New IMS/ IMWG Definition of High Risk Myeloma. @JCO_ASCO #IMWG25 @Myeloma_Society @IMFmyeloma @NikhilMunshiMD @mvmateos @SagarLonialMD @szusmani @NoopurRajeMD
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
Fantastic results! Also today in the @nytimes @PlasmaCellPete @MyelomaRnD nytimes.com/2025/06/03/hea…
‼️ #ASCO25 simultaneous publication by Jagannath et al: Long-Term (≥5 year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory #MultipleMyeloma. Read the full article: brnw.ch/21wT7Gn
‼️#ASCO25 simultaneous publication by Ailawadhi et al: Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. Read more: brnw.ch/21wT7Gq #MMSM
To hear @SLentzsch and myself on a related topic (high-risk #MYELOMA) in our recent @JCO_ASCO Editorial Fellow podcast: music.youtube.com/watch?v=iHockd… @columbiacancer